Efficacy and tolerability of serotonin transport inhibitors in obsessive-compulsive disorder. A meta-analysis.
about
World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Pharmacological Treatment of Anxiety, Obsessive-Compulsive and Posttraumatic Stress DisordersCurrent trends in drug treatment of obsessive–compulsive disorderCurrent and potential pharmacological treatments for obsessive-compulsive disorderSelective serotonin re-uptake inhibitors (SSRIs) versus placebo for obsessive compulsive disorder (OCD)Serotonin re-uptake Inhibitors (SSRIs) versus placebo for obsessive compulsive disorders (OCD)Catechol-O-methyltransferase-deficient mice exhibit sexually dimorphic changes in catecholamine levels and behavior.Vasopressin-dependent flank marking in golden hamsters is suppressed by drugs used in the treatment of obsessive-compulsive disorderCanadian clinical practice guidelines for the management of anxiety, posttraumatic stress and obsessive-compulsive disordersExcluding the typical patient: thirty years of pharmacotherapy efficacy trials for obsessive-compulsive disorderHow the serotonin story is being rewritten by new gene-based discoveries principally related to SLC6A4, the serotonin transporter gene, which functions to influence all cellular serotonin systems.Integrating evidence from neuroimaging and neuropsychological studies of obsessive-compulsive disorder: the orbitofronto-striatal model revisited.Obsessive-compulsive disorder. What to do if you recognize baffling behavior.Family involvement in the psychological treatment of obsessive-compulsive disorder: a meta-analysis.On the pharmacotherapy of obsessive-compulsive disorder: is a consensus possible?Eating disorder and obsessive-compulsive disorder: neurochemical and phenomenological commonalities.Use of clomipramine in treatment of obsessive-compulsive disorder, separation anxiety and noise phobia in dogs: a preliminary, clinical study.Rapid effects of brief intensive cognitive-behavioral therapy on brain glucose metabolism in obsessive-compulsive disorder.More than Medication-Achieving Goals through Psychotherapy in Patients with Obsessive Compulsive Disorder.The placebo response in social phobia.Therapeutic approaches to the treatment of refractory obsessive-compulsive disorder.Psychopharmacology of anxiety disorders.Obsessive compulsive neurosis : clomipramine, prolactin and therapeutic response.Anxiety and Depression: Optimizing Treatments.Symptomatic and syndromal anxiety and depression.Anxiety disorders and major depression, together or apart.Trichotillomania. Presentation, etiology, diagnosis and therapy.Use of clomipramine in the treatment of anxiety-related and obsessive-compulsive disorders in cats.Pharmacotherapies in the management of obsessive-compulsive disorder.Pharmacotherapy of childhood anxiety disorders.Pharmacotherapy of anxious disorders.Insight in obsessive compulsive disorder and body dysmorphic disorderPsychotherapy and medication management strategies for obsessive-compulsive disorder.Augmenting treatment of obsessive-compulsive disorder with Antonovsky's sense of coherence theory.Gray matter volumes in obsessive-compulsive disorder before and after fluoxetine or cognitive-behavior therapy: a randomized clinical trial.Pharmacotherapy of anxiety disorders: a critical reviewA time-limited behavioral group for treatment of obsessive-compulsive disorder.Acceptance and Commitment Therapy, Selective Serotonin Reuptake Inhibitors and Their Combination in the Improvement of Obsessive-Compulsive Symptoms and Experiential Avoidance in Patients With Obsessive-Compulsive DisorderObsessive-compulsive disorder: a critical review of therapeutic perspectives.Genotype determining low catechol-O-methyltransferase activity as a risk factor for obsessive-compulsive disorder.A promising randomized trial of a new therapy for obsessive-compulsive disorder.
P2860
Q22305681-16DE2987-1916-4565-83A0-E704CE52BCAAQ22305853-4AAC2E1C-FF58-4F78-AE63-9D4655F715EDQ22306025-CA56F457-6E16-4F2A-8D71-09FDF7759054Q24242402-EA341C1D-48F9-4984-B40E-426D78F736B2Q24244476-394A099C-E155-4EF7-9D89-A65A71C28751Q24671972-F00B1E00-AB71-4E34-BC55-64F56650A042Q24803880-DD02CC88-6E20-41F7-83B5-A9255A46A924Q27009995-BADB838A-A1D6-400E-AE36-5CE48A03C8E6Q27025821-455A627B-8E2B-4462-8F9F-25DC8DC75DD1Q30485725-3E293FC3-218F-49F9-932F-92CB900FD20BQ31139048-0508E990-CBD6-4EA9-9529-902218E86E25Q33802581-7C1D597E-3593-4AFA-BA70-E9F5A009391AQ33860943-9CC91F08-B176-4204-857C-4FB9856A64A6Q33898364-4E7576E5-8D51-4A0A-A2D2-27E8D534A2E8Q33921668-05F5F95E-3AEA-4E94-9D2D-1DF9397E1218Q33946432-B9EC73CB-1619-47C3-94E2-14EE39473C03Q33946894-484DAFA6-270D-4ACA-A7DA-3E470C5C6268Q34068960-C2B30010-E6EB-4C9C-A549-D80D62A23E17Q34091943-2C8EE416-D3E8-4652-BAF4-1D0DD13A9BF6Q34108465-9743BD4E-5AC1-47BA-B561-D775C90DBEC5Q34228150-A8176DFA-07C1-4E8D-9D20-B0DBC263E0DFQ34256200-2D243512-7C85-4809-9DDF-84F668AF57FBQ34304950-D487D5AA-6F63-43B3-9FC7-B214E89466ACQ34415522-97F9729D-F435-466F-9726-FECAC3CF0C33Q34415535-72281F71-B6F3-48F0-BDDF-1D0EDD0B94B8Q34447904-CD964614-D814-4599-8DF2-A9E614DD6007Q34472286-ADD1FE44-0F7C-4118-A115-0733157F922DQ34547177-578BACB5-1574-4DDE-840D-80063C7CA3BFQ34749190-862A8C46-7A0C-4B45-8C95-5A3B8242A0B3Q35011794-213DAA10-5096-4EC2-82C2-14B4F22E539CQ35095139-42E26993-B0A2-49BB-9758-AE01B1273A9BQ35212987-42140AF5-901D-42F2-941F-BAFAA774A744Q35635442-596FD78E-6D77-4DE7-AD25-E142F5E4E26CQ35679963-D0CBC9FF-8BA0-4CF2-A57B-45EF4E57B66BQ35686859-0F93B953-19D5-4211-AAA3-856EFAB603A3Q35900163-D765662F-24C8-41EA-8BB7-62D50BC6B4DAQ35964390-6DD40913-4B63-40B1-87FC-A7C6B8737726Q36058933-749BBFB3-231D-4345-A4E1-548BED4A567DQ36139662-C303723E-3120-4D0A-A8A9-EB7027BEF78FQ36206009-088E8027-EDD1-4B41-944E-5A41500F0C2D
P2860
Efficacy and tolerability of serotonin transport inhibitors in obsessive-compulsive disorder. A meta-analysis.
description
1995 nî lūn-bûn
@nan
1995 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
1995 թվականի հունվարին հրատարակված գիտական հոդված
@hy
1995年の論文
@ja
1995年論文
@yue
1995年論文
@zh-hant
1995年論文
@zh-hk
1995年論文
@zh-mo
1995年論文
@zh-tw
1995年论文
@wuu
name
Efficacy and tolerability of s ...... ive disorder. A meta-analysis.
@ast
Efficacy and tolerability of s ...... ive disorder. A meta-analysis.
@en
Efficacy and tolerability of s ...... ive disorder. A meta-analysis.
@nl
type
label
Efficacy and tolerability of s ...... ive disorder. A meta-analysis.
@ast
Efficacy and tolerability of s ...... ive disorder. A meta-analysis.
@en
Efficacy and tolerability of s ...... ive disorder. A meta-analysis.
@nl
prefLabel
Efficacy and tolerability of s ...... ive disorder. A meta-analysis.
@ast
Efficacy and tolerability of s ...... ive disorder. A meta-analysis.
@en
Efficacy and tolerability of s ...... ive disorder. A meta-analysis.
@nl
P2093
P1433
P1476
Efficacy and tolerability of s ...... ive disorder. A meta-analysis.
@en
P2093
Jefferson JW
Katzelnick DJ
P356
10.1001/ARCHPSYC.1995.03950130053006
P407
P577
1995-01-01T00:00:00Z